alle terapie convenzionali, con un ottimo profilo di sicurezza. Sono stati ottenuti

CONCLUSIONI

La granulocito-monocito aferesi è risultata un trattamento efficace nel ritardare

l’intervento chirurgico in pazienti affetti da MICI in fase moderata-severa e resistenti

alle terapie convenzionali, con un ottimo profilo di sicurezza. Sono stati ottenuti

buoni risultati sulla qualità di vita e sul controllo dell’attività clinica di queste

patologie e soprattutto sulla guarigione endoscopica delle lesioni. Appare pertanto

una metodica innovativa e promettente da poter essere inserita nella terapia delle

MICI, una volta che studi condotti su casistiche più numerose e con un follow-up di

più lunga durata ne avranno valutato l’efficacia a lungo termine.

BIBLIOGRAFIA

1. Hendrickson B. A., Gokhale R., Cho J. H. Clinical aspects and

pathophysiology of inflammatory bowel disease. Clinical Microbiology Reviews 2002; 15(1): 79-94.

2. Strober W., Fuss I., Mannon P. The fundamental basis of inflammatory

bowel disease. J. Clin. Invest. 2007; 117: 514-121.

3. Roseth A.G., Aadland E., Jahnsen J., et al. Assessment of disease activity

in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion 1997; 58: 176-180.

4. Saverymuttu S.H., Camilleri M., Rees H., et al. Indium 111 granulocyte

scanning in the assessment of disease extent and disease activity in inflammatory bowel disease. A comparison with colonoscopy, histology, and fecal indium 111-granulocyte excretion. Gastroenterol 1986; 90: 1121-1128.

5. Costa F., Mumolo MG., Ceccarelli L., et al. Calprotectin is a stronger

predictive marker of relapse in ulcerative colitis than in Crohn’s disease. Gut 2005; 54(3): 364-8.

6. Best WR, Becktel JM, Singleton JW. Re-derived value of the eight

coefficients of the Crohn's disease activity index (CDAI). Gastroenterology 1979;77:843-846.

7. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.

Br Med J 1989;298:82-86.

8. Eaden J. Review article: the data supporting a role for aminosalicylates in

the chemoprevention of colorectal cancer in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2003; 18(suppl 2):15-21.

9. Kuhbacher T., Fölsch UR. Practical guidelines for the treatment of

inflammatory bowel disease. World J Gastroeneterol 2007; 13(8): 1149- 1155.

10. Rutgeerts P., Sandborn WJ., Feagan BG., et al. Infliximab for induction

and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353(23):

2462-76.

11. Kohn A., Daperno M., Armuzzi A., et al. Infliximab in severe ulcerative

colitis: short-term results of different infusion regimens and long-term follow-up. Aliment Pharmacol Ther 2007; 26: 747-756.

12. Tabuchi T., Ubukata H., Saniabadi AR., et al. Granulocyte apheresis as a

possibile new approach in cancer therapy: a pilot study involving two cases.

Cancer Detect Prev 1999; 23(5): 417-21.

13. Fujimori J., Yoshino S., et al. Improvement in rheumathoid arthritis

following application of an extracorporeal granulotrap column, G-1.

Rheumatol Int 1996; 15(5): 175-80.

14. Ohara M., Saniabadi AR., et al. Granulocytapheresis in the treatment of

patients with rheumatoid arthritis. Artif Organs 1997; 21(9): 989-94.

15. Saniabadi AR., Hanai H., Suzuki Y., et al. Adacolumn for selective

leukocytapheresis as a non-pharmacological treatment for patients with

disorders of the immune system: an adjunct or an alternative to drug therapy?

J Clin Apher 2005; 20(3): 166-7.

16. Hiraishi K., Takeda Y., Shiobara N., et al. Studies on the mechanisms of

leukocyte adhesion to cellulose acetate beads: an in vitro model to assess the efficacy of cellulose acetate carrier-based granulocyte and monocyte adsorptive apheresis. Ther Apher Dial 2003; 7(3): 331-340.

17. Ramlow W., Emmrich J., Ahrenholz P., et al. In vivo and in vitro

evaluation of Adacolumn cytapheresis in healthy subjects. J Clin Apher 2005;

19: 1-9.

18. Takemoto K., Kato J., Kuriyama M., et al. Predictive factors of efficacy

of leukocytapheresis for steroid-resistant ulcerative colitis patients. Dig Liv Dis 2007; 39: 422-429.

19. Hanai H., Watanabe F., Takeuchi K., et al. Leukocyte adsorptive

apheresis for the treatment of active ulcerative colitis: a prospective, uncontrolled, pilot study. Clin Gastroenterol Hepatol 2003; 1: 28-35.

20. Hanai H. Position of selective leukocytapheresis in the medical therapy of

ulcerative colitis. World J Gastroenterol 2006; 12(47): 7568-7577.

21. Suzuki Y., Yoshimura N., Saniabadi AR., et al. Selective granulocyte and

monocyte adsorptive apheresis as a first line treatment for steroid naïve

patients with active ulcerative colitis: a prospective uncontrolled study. Dig

Dis Sci 2004; 49(4): 565-71.

22. Matsui T., Nishimura T., Matake H., et al. Granulocytapheresis for

Crohn’s disease: a report on seven refractory patients. Am J Gastroenterol 2003; 98(2): 511-2.

23. Maiden L., Baur R., Takeuchi K., et al. Adacolumn apheresis reduces

relapse rates in patients with IBD at significant risk of clinical relapse (abstract). Gut 2005; 54 (suppl NOVII): A57.

24. Shimoyama T., Sawada K., Hiwatashi N., et al. Safety and efficacy of

granulocyte and monocyte adsorption apheresis in patients with active ulcerative colitis: a multicenter study. J Clin Apher 2001; 16:1-9.

25. Riley SA., Mani V., Goodman MJ., et al. Microscopic activity in ulcerative

colitis: what does it mean? Gut 1991; 32:174-8.

26. Modigliani R. Endoscopic management of inflammatory bowel disease. Am J Gastroeneterol 1994; 89 (suppl 8): 53-65.

27. D’Haens GR., Noman M., Baert F., et al. Endoscopic healing after

infliximab treatment for Crohn’s disease provides a long time in relapse.

Gastroenterol 2002; 122: A100.

28. Ricart E., Esteve M., Andreu M., et al. Evaluation of 5 versus 10

granuloyteapheresis sessions in steroid-dipendent ulcerative colitis: a pilot, prospective, multicenter, randomized study. World J Gastroenterol 2007;

13(15): 2193-2197.

29. Kanke K., Nakano M., Hiraishi H., et al. Evaluation of

granulocyte/monocyte apheresis therapy for active ulcerative colitis. Dig Liv Dis 2004; 36: 512-518.

30. Fukuda M., Matsui T., Suzuki Y., et al. Adsorptive granulocyte and

monocyte apheresis for refractory Crohn’s disease: an open multicenter prospective study. J Gastroenterol 2004; 39(12): 1158-64.

31. Caprilli R., D’Ovidio V. Leukocytapheresis as promising therapy for

inflammatory bowel disease. Dig Liv Dis 2007; 39:435-437.

32. Domenech E., Hinojosa J., Esteve-Comas M., et al. Granulocyteapheresis

in steroid-dependent inflammatory bowel disease: a prospective, open, pilot

study. Aliment Pharmacol Ther 2004; 20:1347-52.